Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Umbilical cord blood-derived CD11c+ dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy

Fig. 5

In vivo cytotoxic T lymphocyte (CTL) assay xenograft model. Representative image from one of the experiments showing average radiance (measured on the in vivo imaging system (IVIS)) from female NOD/SCID mice bearing tumor consisting of MCF-7-luc-F5 cells. a, b Average radiance from a control mouse on day 0 and day 10. c and d, e and f Average radiance from the umbilical cord blood (UCB)/peripheral blood (PBL)-CTLs group of mice on day 0 and day 10 post CTLs infusion. g Average radiance data of three experiments on day 0 and day 10 post CTLs infusion. There was significant regression in the tumor in both treatment groups infused with pulsed UCB/PBL-CTLs. Horizontal lines mean values ± SD. h Tumor volume on day 0 and day 10 post CTLs infusion. Similar significant reduction in the tumor mass was observed in both treatment groups infused with pulsed UCB/PBL-CTLs. i, j H&E-stained section of MCF-7-luc-F5 cell xenograft tumor from a control mouse showing no infiltrating T cells. k and l, m and n H&E-stained sections from a mouse infused with pulsed UCB/PBL-CTLs. Infiltrating CTLs in both treatment groups are observed (arrows). o-q Immunofluorescence images of sections stained with anti-human CD3 Ab, which further confirms the absence and presence of CTLs in the control and treatment group infused with pulsed UCB/PBL-CTLs, respectively. r Quantification of tumor-infiltrating T cells, which was enumerated by Z stack using the Zeiss confocal microscope. Data shown are mean ± SD, n = 3 (*P <0.05, ** P <0.01, *** P <0.001)

Back to article page